Literature DB >> 31626560

Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California.

Nicolas A Menzies1, Andrea Parriott2, Sourya Shrestha3, David W Dowdy3, Ted Cohen4, Joshua A Salomon5, Suzanne M Marks6, Andrew N Hill6, Carla A Winston6, Garrett R Asay6, Pennan Barry7, Adam Readhead7, Jennifer Flood7, James G Kahn2,8, Priya B Shete9.   

Abstract

Rationale: Mathematical modeling is used to understand disease dynamics, forecast trends, and inform public health prioritization. We conducted a comparative analysis of tuberculosis (TB) epidemiology and potential intervention effects in California, using three previously developed epidemiologic models of TB.
Objectives: To compare the influence of various modeling methods and assumptions on epidemiologic projections of domestic latent TB infection (LTBI) control interventions in California.
Methods: We compared model results between 2005 and 2050 under a base-case scenario representing current TB services and alternative scenarios including: 1) sustained interruption of Mycobacterium tuberculosis (Mtb) transmission, 2) sustained resolution of LTBI and TB prior to entry of new residents, and 3) one-time targeted testing and treatment of LTBI among 25% of non-U.S.-born individuals residing in California.Measurements and Main
Results: Model estimates of TB cases and deaths in California were in close agreement over the historical period but diverged for LTBI prevalence and new Mtb infections-outcomes for which definitive data are unavailable. Between 2018 and 2050, models projected average annual declines of 0.58-1.42% in TB cases, without additional interventions. A one-time LTBI testing and treatment intervention among non-U.S.-born residents was projected to produce sustained reductions in TB incidence. Models found prevalent Mtb infection and migration to be more significant drivers of future TB incidence than local transmission.Conclusions: All models projected a stagnation in the decline of TB incidence, highlighting the need for additional interventions including greater access to LTBI diagnosis and treatment for non-U.S.-born individuals. Differences in model results reflect gaps in historical data and uncertainty in the trends of key parameters, demonstrating the need for high-quality, up-to-date data on TB determinants and outcomes.

Entities:  

Keywords:  immigration; infectious disease modeling; latent tuberculosis infection; public health; tuberculosis

Mesh:

Year:  2020        PMID: 31626560      PMCID: PMC7464931          DOI: 10.1164/rccm.201907-1289OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  27 in total

1.  Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-12-09       Impact factor: 17.586

2.  Current and future trends in tuberculosis incidence in New York City: a dynamic modelling analysis.

Authors:  Anthony T Fojo; Natalie L Stennis; Andrew S Azman; Emily A Kendall; Sourya Shrestha; Shama D Ahuja; David W Dowdy
Journal:  Lancet Public Health       Date:  2017-07

3.  Optimally capturing latency dynamics in models of tuberculosis transmission.

Authors:  Romain Ragonnet; James M Trauer; Nick Scott; Michael T Meehan; Justin T Denholm; Emma S McBryde
Journal:  Epidemics       Date:  2017-06-16       Impact factor: 4.396

4.  The Prevalence of Latent Tuberculosis Infection in the United States.

Authors:  James D Mancuso; Jeffrey M Diffenderfer; Bijan J Ghassemieh; David J Horne; Tzu-Cheg Kao
Journal:  Am J Respir Crit Care Med       Date:  2016-08-15       Impact factor: 21.405

Review 5.  Data needs for evidence-based decisions: a tuberculosis modeler's 'wish list'.

Authors:  D W Dowdy; C Dye; T Cohen
Journal:  Int J Tuberc Lung Dis       Date:  2013-07       Impact factor: 2.373

6.  Modelling tuberculosis trends in the USA.

Authors:  A N Hill; J E Becerra; K G Castro
Journal:  Epidemiol Infect       Date:  2012-01-11       Impact factor: 2.451

7.  Impact and Effectiveness of State-Level Tuberculosis Interventions in California, Florida, New York, and Texas: A Model-Based Analysis.

Authors:  Sourya Shrestha; Sarah Cherng; Andrew N Hill; Sue Reynolds; Jennifer Flood; Pennan M Barry; Adam Readhead; Margaret Oxtoby; Michael Lauzardo; Tom Privett; Suzanne M Marks; David W Dowdy
Journal:  Am J Epidemiol       Date:  2019-09-01       Impact factor: 4.897

8.  Estimating tuberculosis cases and their economic costs averted in the United States over the past two decades.

Authors:  K G Castro; S M Marks; M P Chen; A N Hill; J E Becerra; R Miramontes; C A Winston; T R Navin; R H Pratt; K H Young; P A LoBue
Journal:  Int J Tuberc Lung Dis       Date:  2016-07       Impact factor: 2.373

9.  Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.

Authors: 
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

10.  Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions.

Authors:  Nicolas A Menzies; Emory Wolf; David Connors; Meghan Bellerose; Alyssa N Sbarra; Ted Cohen; Andrew N Hill; Reza Yaesoubi; Kara Galer; Peter J White; Ibrahim Abubakar; Joshua A Salomon
Journal:  Lancet Infect Dis       Date:  2018-04-10       Impact factor: 25.071

View more
  6 in total

1.  Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination.

Authors:  Suzanne M Marks; David W Dowdy; Nicolas A Menzies; Priya B Shete; Joshua A Salomon; Andrea Parriott; Sourya Shrestha; Jennifer Flood; Andrew N Hill
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

2.  The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease.

Authors:  Nicolas A Menzies; Sourya Shrestha; Andrea Parriott; Suzanne M Marks; Andrew N Hill; David W Dowdy; Priya B Shete; Ted Cohen; Joshua A Salomon
Journal:  Epidemiology       Date:  2022-01-01       Impact factor: 4.822

3.  Estimated Population-Level Impact of Using a Six-Week Regimen of Daily Rifapentine to Treat Latent Tuberculosis Infection in the United States.

Authors:  Sourya Shrestha; Andrea Parriott; Nicolas A Menzies; Priya B Shete; Andrew N Hill; Suzanne M Marks; David W Dowdy
Journal:  Ann Am Thorac Soc       Date:  2020-12

4.  Use of Modeling to Inform Tuberculosis Elimination Strategies.

Authors:  Masahiro Narita; Jeanne Sullivan Meissner; Joseph Burzynski
Journal:  Am J Respir Crit Care Med       Date:  2020-02-01       Impact factor: 21.405

5.  Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States.

Authors:  Nicolas A Menzies; Meghan Bellerose; Christian Testa; Nicole A Swartwood; Yelena Malyuta; Ted Cohen; Suzanne M Marks; Andrew N Hill; Anand A Date; Susan A Maloney; Sarah E Bowden; Ardath W Grills; Joshua A Salomon
Journal:  Am J Respir Crit Care Med       Date:  2020-12-01       Impact factor: 21.405

6.  Time Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States.

Authors:  Nicolas A Menzies; Nicole Swartwood; Christian Testa; Yelena Malyuta; Andrew N Hill; Suzanne M Marks; Ted Cohen; Joshua A Salomon
Journal:  Epidemiology       Date:  2021-01       Impact factor: 4.860

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.